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Background: To date only a handful of drugs are available for the treatment of melanoma. Among them
vemurafenib, a BrafV600E specific inhibitor, showed promising results in terms of response rate and increase in
median survival time. However, its effectiveness is limited by development of resistance and the search for
additional drugs for melanoma treatment is ongoing. The present study was performed to analyze the correlation
between Braf expression and the expression of p300, a known down stream target of the mitogen activated
protein kinase (MAPK) pathway, which was recently shown by us to be a prognostic marker for melanoma
progression and patient survival.
Methods: The expression of Braf and p300 expression were correlated and analyzed by Chi-square test. A total of
327 melanoma patient cases (193 primary melanoma and 134 metastatic melanoma) were used for the study.
Classification & regression tree (CRT), Kaplan-Meier, and multivariate Cox regression analysis were used to elucidate
the significance of the combination of Braf and p300 expression in the diagnosis and prognosis of melanoma.
Results: Our results demonstrate that Braf expression is inversely correlated with nuclear p300 and positively
correlated with cytoplasmic p300 expression. Braf and cytoplasmic p300 were found to be associated with
melanoma progression, tumor size and ulceration status. CRT analysis revealed that a combination of Braf and p300
expression (nuclear and cytoplasmic), could be used to distinguish between nevi and melanoma, and primary from
metastatic melanoma lesions. The combination of Braf and nuclear p300 was significantly associated with patient
survival and nuclear p300 was found to be an independent predictor of patient survival.
Conclusion: Our results indicate a cross-talk between Braf and p300 in melanoma and demonstrate the importance
Braf and p300 expression in the diagnosis and prognosis of melanoma.
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Melanoma, a type of cancer caused due to uncontrolled
proliferation of melanocytes in epidermis of skin, is one
of the most frequent cancers in fair skinned populations
[1,2]. According to recently published statistics based on
data from United States of America, it is the fifth most
common cancer in men and seventh most common can-
cer in women [3]. Melanoma is known for its rapid
progression, metastasis, and poor prognosis, and is re-
sponsible for over 80% of deaths from skin cancer [1].* Correspondence: anand.rotte@gmail.com
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unless otherwise stated.Early diagnosis allows for surgical excision of the tumors
and the patients can be managed with a relapse free
interval of up to 10 years [4,5]. But, approximately 1 in
35 patients develop metastatic tumors, and metastatic
melanoma has a very poor prognosis with an overall sur-
vival between 8 to 18 months. Only 15% of patients with
metastatic melanoma survive for 5 years [3,6].
There has been limited progress in the treatment of
melanoma; metastatic melanoma is notorious for its re-
sistance to conventional radiotherapy and chemotherapy.
Until recently, dacarbazine, a DNA alkylating agent, was
the only FDA approved drug available for the treatment
of melanoma [6]. In 2011, vemurafenib, a specific inhibi-
tor of BrafV600E (BRAF harbouring a point mutationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with glutamine), and ipilimumab, a monoclonal antibody
against cytotoxic T-lymphocyte associated antigen 4
(CTLA-4), have been approved for the treatment of mel-
anoma [6]. However, the success of their use is limited
by effectiveness only in a restricted population, potential
development of lethal resistance with vemurafenib treat-
ment, and only a small increase in median survival time
in the case of ipilimumab [6]. Our lab previously
reported a significant association between increased Braf
expression and melanoma progression, and an inverse
relationship between Braf expression and patient
prognosis [7,8]. Considering the significance of Braf
inhibitors in melanoma treatment, several studies have
attempted to decipher the mechanisms for resistance
and suggested both mitogen activated protein kinase
(MAP kinase) dependent and independent pathways as
reasons for vemurafenib resistance [6]. A number of
strategies to overcome the resistance, including a com-
bination therapy of Braf and MEK1/2 inhibitors, have
been proposed and are in various stages of clinical stud-
ies [6]. However, there are no results on the efficiency of
the combination therapies in clinical settings and the
search for alternative and additional drugs for the treat-
ment of melanoma is ongoing.
We analyzed the expression of p300, a well studied
histone acetyl transferase (HAT) [9], in melanoma pa-
tient samples and found that loss of p300 expression in
the nucleus was correlated with disease progression and
worse survival in melanoma patients [10]. Furthermore,
we also found that nuclear p300 expression was an inde-
pendent prognostic factor, suggesting the importance of
targeting the functions of histone acetyltransferases
(HAT) in melanoma therapy [10]. Stability and activity
of p300 protein have been shown to be regulated by
phosphorylation, and phosphorylation of p300 by mito-
gen activated protein kinase (MAPK) and extracellular
signal-regulated kinase (ERK1/2) has been reported to
promote the degradation of p300 protein [11,12]. Since
our previous studies in melanoma patients showed an
increase in Braf expression, which is known to be up-
stream of MAPK in the signaling cascade, we hypothe-
sized a potential for correlation between p300 and Braf
[8]. To test our hypothesis, and to explore the possible
opportunity of targeting histone acetylation and Braf in
melanoma treatment, we studied the association be-
tween p300 and Braf expression in patient samples.
Methods
Patient specimens and tissue microarray construction
The collection of patient specimens and the construction
of the tissue microarray (TMA) have been previously de-
scribed [13]. Briefly, we used patient data collected from
1990 to 2009. Of 748 patients specimens collected, 369biopsies including 327 melanoma cases (193 primary mel-
anoma and 134 metastatic melanoma) and 42 cases of nevi
(21 normal nevi and 21 dysplastic nevi) could be evaluated
for comparing p300 and Braf staining in this study, due to
loss of biopsy cores or insufficient tumor cells present in
the cores. The demographic characteristics of melanoma
patients are detailed in Table 1. All specimens were ob-
tained from the archives of the Department of Pathology,
Vancouver General Hospital. The use of human skin tissues
and the waiver of patient consent in this study were ap-
proved by the Clinical Research Ethics Board of the Univer-
sity of British Columbia [14]. The study was conducted
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Helsinki.
From the original tissue biopsies, the most representa-
tive tumor area was carefully selected and marked on
hematoxylin and eosin stained slides. Tissue cores of 0.6-
mm thickness were taken in duplicate from each biopsy
and the TMAs were assembled using a tissue-array instru-
ment (Beecher Instruments, Silver Spring, MD). Using a
Leica microtome, multiple 4 μM sections were cut and
transferred to adhesive-coated slides using regular histo-
logical procedures. One section from each TMA was rou-
tinely stained with hematoxylin and eosin while the
remaining sections were stored at room temperature for
immunohistochemical staining.
Immunohistochemistry
Tissue microarray (TMA) slides were dewaxed at 55°C for
20 min followed by three 5 min washes with xylene. The
tissues were then rehydrated by washing the slides for
5 min each with 100%, 95%, 80% ethanol and finally with
distilled water. The slides were then heated to 95°C for
30 min in 10 mmol/L sodium citrate (pH 6.0) for antigen
retrieval and then treated with 3% hydrogen peroxide for
1 hour to block the endogenous peroxidase activity. After
blocking the slides with the universal blocking serum (Dako
Diagnostics, Carpinteria, CA, USA), the sections were incu-
bated overnight with monoclonal mouse anti-p300 anti-
body (1:50 dilution; Millipore, USA) or with mouse
polyclonal anti-Braf antibody (1:100 dilution; Sigma, USA)
at 4°C. The sections were then incubated for 30 min
with a biotin-labeled secondary antibody and then with
streptavidin-peroxidase (Dako Diagnostics). The samples
were developed by treatment with 3,3′-diamino-benzidine
substrate (Vector Laboratories, Burlington, Ontario,
Canada) and with hematoxylin to counter-stain the nuclei.
Negative controls were done by omitting the p300/Braf
antibody during the primary antibody incubation.
Evaluation of immunostaining
The evaluation of p300 and Braf staining was done blindly
by microscopic examination of the tissue sections by one
dermatopathologist and two other observers simultan-
eously, using a multiple viewing microscope and a consen-
sus was reached for the score of each core. p300/Braf
staining intensity was scored as 0+, 1+, 2+, 3+ whereas the
percentage of p300/Braf positive cells was scored as 1 (1-
25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%). In cases of
discrepancy between duplicated cores, the higher score
from the two tissue cores was taken as the final score. The
product of intensity and percentage was taken as the im-
munoreactive score (IRS) [15]. Based on IRS, p300 & Braf
staining in the tissue sections was categorized as negative
(IRS 0), weak (IRS 1–4), moderate (IRS 6–8), or strong (IRS
9–12). Since p300 was found to be expressed in bothnucleus and cytoplasm [10], the nuclear and cytoplasmic
staining was evaluated in parallel at the same time. The
choice of the optimum cut-off values for the IRS were de-
rived based on the IRS pattern in nevi and melanoma cases
and are described previously [7,10].
Statistical analysis
Correlation between p300 and Braf, and clinicopathologic
parameters was evaluated by Chi-square test among the pa-
tient subgroups. Survival time was calculated from the date
of melanoma diagnosis to the date of death or last follow-
up. The effect of p300 and Braf on the overall and disease-
specific survival was evaluated by Kaplan-Meier analysis
and log-rank test. Additionally, multivariate Cox propor-
tional hazards regression models were preformed to esti-
mate the hazard ratios (HRs) and their 95% confidential
intervals (CIs). Classification tree was constructed by the
classification and regression tree (CRT) model as described
previously to examine possibility of using a Braf and p300
combination to identify different stages of melanoma [16].
The decision trees depicting the classification rules were
generated through recursive partitioning. When growing
each tree, equal prior probabilities to the normal and can-
cer cohorts, and equal misclassification costs were assigned.
To assess the amount of over-fitting, 10-fold cross-
validation experiments was performed using the SE rule as
described previously [16]. P-value <0.05 was considered as
statistically significant. All the statistical analyses were per-
formed using SPSS version 16.0 (SPSS Inc, Chicago, IL)
software.
Results
Braf expression correlates inversely with nuclear p300
and directly with cytoplasmic p300 expression
Previous studies showed that phosphorylation by MAP kin-
ase resulted in accelerated degradation of p300 in cardiac
cells [11]. Since Braf is known to be an up stream kinase in
the MAP kinase pathway, we asked if its expression could
be inversely associated with p300 expression in the tumor
samples from melanoma patients. Based on the previously
reported cut-off values for immunoreactive scores (IRS), we
divided the staining into low (IRS 0 to 4) and high (IRS
6 to 12), and matched the expression of Braf and p300
in the melanoma patients [7,10]. Chi-square analysis of
the matched data revealed that Braf expression inversely
correlated with nuclear p300 and directly correlated
with cytoplasmic p300 expression suggesting Braf nega-
tively regulates the nuclear accumulation of p300
(Figure 1A & B).
Braf and cytoplasmic p300 expression are associated with
disease progression
We next asked if the association between Braf and p300
expression was particularly correlated with disease
Figure 1 Braf expression correlates with p300 expression in melanoma patients. (A) Negative correlation between Braf and nuclear p300
expression in melanoma patient biopsies. Melanomas which have high Braf expression have a significantly higher percentage of low nuclear
p300 staining (p = 0.006, χ2 test). (B) Positive correlation between Braf and cytoplasmic p300 expression in melanoma patient biopsies.
Melanomas which have high Braf expression also have a significantly higher percentage of high cytoplasmic p300 staining (p = 0.001, χ2 test).
High Braf and high cytoplasmic p300 expression is significantly associated with AJCC progression (C) and tumor size (D), but not with ulceration
status (E). p-values, 8.7×10−5, 0.001 & 0.119 respectively (χ2 test).
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divided the data based on American Joint Committee for
Cancer (AJCC) staging and performed Chi-square test
analysis. As shown in Table 2, the percentage of patients
with high Braf expression or high cytoplasmic expression
was significantly increased as melanoma progressed
from AJCC stage I to stage III and then slightly de-
creased from stage III to stage IV. Accordingly, the per-
centage of patients with high Braf and high cytoplasmic
p300 expression was significantly increased from AJCC
stage I through stage III and slightly decreased from
stage III to stage IV (Figure 1C). Interestingly, the differ-
ence in percentage of patients with high Braf and high
cytoplasmic p300 expression was highest between stage I
and II, which differ mainly based on the tumor size(Figure 1C) [17]. On the other hand, increase in the per-
centage of cases with high Braf and low nuclear p300 ex-
pression was more apparent between stages II and III,
which differ based on the presence of tumor cells in the
lymph nodes, an indicator of migration and metastasis
(Table 2) [17].
Next we separated the cases based on tumor size (≤2 mm
versus >2 mm) and then based on ulceration status (no ul-
ceration versus ulceration). Braf expression was found to be
significantly associated with tumor size and ulceration sta-
tus, whereas cytoplasmic p300 expression was associated
with tumor size but not with ulceration status (Table 3).
Nuclear p300 expression was not associated with tumor
size or ulceration status (Table 3). As seen with melanoma
progression, the incidence of larger tumors was significantly
Table 2 Correlation between Braf/p300 staining and AJCC stage in 327 melanoma patients
Stage I Stage II Stage III Stage IV p-value*
Braf
Low 37 (46.3%) 26 (23.0%) 11 (20.0%) 20 (25.3%) 9.8 × 10−4
High 43 (53.8%) 87 (77.0%) 44 (80.0%) 59 (74.7%)
Nuclear p300
Low 29 (36.3%) 47 (41.6%) 30 (54.5%) 33 (41.8%) 0.204
High 51 (63.7%) 66 (58.4%) 25 (45.5%) 46 (59.2%)
Cytoplasmic p300
Low 48 (60.0%) 53 (46.9%) 17 (30.9%) 36 (45.6%) 0.011
High 32 (40.0%) 60 (53.1%) 38 (69.1%) 43 (54.4%)
Braf and nuclear p300
Low braf low p300 11 (13.8%) 13 (11.5%) 6 (10.9%) 6 (7.6%) 0.010
Low braf high p300 26 (32.5%) 14 (12.4%) 6 (10.9%) 16 (20.3%)
High braf low p300 18 (22.5%) 34 (30.1%) 24 (43.6%) 27 (34.2%)
High braf high p300 25 (31.3%) 52 (46.0%) 19 (34.6%) 30 (38.0%)
Braf and cytoplasmic p300
Low braf low p300 21 (26.3%) 19 (16.8%) 5 (9.1%) 7 (8.8%) 8.7 × 10−5
Low braf high p300 16 (20.0%) 7 (6.2%) 6 (10.9%) 13 (16.5%)
High braf low p300 27 (33.7%) 34 (30.1%) 12 (21.8%) 29 (36.7%)
High braf high p300 16 (20.0%) 53 (46.9%) 32 (58.2%) 30 (38.0%)
*- χ2 test.
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tended to be higher (Figure 1D), in patients with high Braf
and high cytoplasmic p300 expression. Though patients
with low nuclear p300 tended to be associated with ad-
vanced stages of melanoma, larger tumor size and presence
of ulcerated tumors, the difference did not reach statistical
significance (Table 3).Combination of Braf and p300 in the diagnosis of
melanoma
Since we found Braf and p300 to be significantly associ-
ated with markers of advanced melanoma stages, we
asked if a combination of Braf and p300 expression
could be used to separate nevi from melanoma in skin
biopsies. Classification and regression tree (CRT) ana-
lysis of the patient expression data was previously shown
to be useful in differentiating nevi and melanoma [16].
We categorized the nevi and melanoma values as
dependent variables and Braf, nuclear p300 and cyto-
plasmic p300 expression as independent variables, and
performed CRT analysis on the data. As seen in Figure 2,
Braf expression was the best marker to predict melan-
oma cases, followed by cytoplasmic p300 expression and
nuclear p300 expression. We then used CRT analysis to
test if the combination of Braf and p300 could be used
to classify the primary melanoma cases and metastaticmelanoma cases. As seen in Figure 3, cytoplasmic p300
expression was the best marker to separate the primary
melanoma from metastatic melanoma cases, which
could be further classified, using Braf and nuclear p300
expression.Combination of Braf and p300 in patient prognosis
In order to test the significance of Braf and p300 in pa-
tient prognosis, we analyzed the correlation between
Braf and p300 expression and patient survival using
Kaplan-Meier analysis. We first confirmed the previously
reported association between nuclear p300 and patient
survival, and then tested a combination of Braf and nu-
clear p300 and studied the 5-year patient survival. As
seen in Figure 4A & B, patients with low nuclear p300
expression had significantly worse 5-year survival. Intri-
guingly, patients with high Braf and low nuclear p300
had significantly worse 5-year survival, and patients with
low Braf and high nuclear p300 had better 5-year sur-
vival, indicating the opposing effects of Braf and nuclear
p300 on patient survival (Figure 5A & B). On the other
hand, a combination of cytoplasmic p300 and Braf
expression tended to be associated with worse prognosis
and the patients with high Braf and high cytoplasmic
p300 had the worst 5-year overall and disease-specific
survival compared to the other categories (Figure 5C
Table 3 Correlation between Braf/p300 staining and
tumor size, and ulceration status in 327 melanoma
patients
Tumor size
≤ 2 mm > 2 mm p-value*
Braf
Low 38 (41.8%) 25 (24.5%) 0.011
High 53 (58.2%) 77 (75.5%)
Nuclear p300
Low 33 (36.3%) 43 (42.2%) 0.403
High 58 (63.7%) 59 (57.8%)
Cytoplasmic p300
Low 55 (60.4%) 46 (45.1%) 0.033
High 36 (39.6%) 56 (54.9%)
Braf and nuclear p300
Low Braf and low p300 11 (12.1%) 13 (12.7%) 0.035
Low Braf and high p300 27 (29.7%) 13 (12.7%)
High Braf and low p300 22 (24.2%) 30 (29.4%)
High Braf and high p300 31 (34.1%) 46 (45.1%)
Braf and cytoplasmic p300
Low Braf and low p300 22 (24.2%) 18 (17.6%) 0.001
Low Braf and high p300 16 (17.6%) 7 (6.9%)
High Braf and low p300 33 (36.2%) 28 (27.5%)




Low 53 (36.8%) 10 (20.4%) 0.034
High 91 (63.2%) 39 (79.6%)
Nuclear p300
Low 55 (38.2%) 21 (42.9%) 0.564
High 89 (61.8%) 28 (57.1%)
Cytoplasmic p300
Low 79 (54.9%) 22 (44.9%) 0.223
High 65 (45.1%) 27 (55.1%)
Braf and nuclear p300
Low Braf and low p300 18 (12.5%) 6 (12.2%) 0.199
Low Braf and high p300 35 (24.3%) 5 (10.2%)
High Braf and low p300 37 (25.7%) 15 (30.6%)
High Braf and high p300 54 (37.5%) 23 (46.9%)
Braf and cytoplasmic p300
Low Braf and low p300 32 (20.8%) 8 (16.3%) 0.119
Low Braf and high p300 21 (13.6%) 2 (4.1%)
High Braf and low p300 47 (30.5%) 14 (28.6%)
High Braf and high p300 54 (35.1%) 25 (51.1%)
*- χ2 test.
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and failed to reach statistical significance.
Nuclear p300 expression independently regulates patient
survival
We then performed multivariate Cox regression analysis to
test if Braf and/or p300 expression could independently
regulate the patient survival. We used AJCC staging, nu-
clear p300, cytoplasmic p300, and Braf expression as vari-
ables in the model. As shown in Table 4, multivariate Cox
regression analysis revealed that AJCC staging and nuclear
p300 were significantly associated with patient survival,
whereas the association between Braf and cytoplasmic
p300, and patient survival did not reach statistical signifi-
cance. Our results are in line with the previously published
data showing that Braf expression was not an independent
prognostic factor. It was suggested that due to the close as-
sociation with the AJCC stages, tumor size and ulceration
status, Braf expression could not independently predict pa-
tient survival [7].
Discussion
The key to successful management of melanoma includes
both early and accurate diagnosis, followed by medical
intervention in the form of surgery and chemotherapy. Ac-
curacy of the diagnosis is particularly important as misdiag-
nosis of the melanoma patients might lead to inadequate
treatment and allow spread of the disease. Melanoma is dis-
tinguished from dysplastic nevi with a fair degree of success
using routine pathological examination, but ambiguous le-
sions could still pose problems due to the wide variation in
morphologic features and because of the overlap in the
clinical and histologic features between dysplastic nevi
and melanoma [16,18-21]. Our results suggest that a
combination of Braf and p300 expression can be used for
differentiating melanoma from nevi. The protocol for im-
munohistochemical staining of the tissue samples is a sim-
ple technique to perform and can give results relatively fast
[22]. Since the expression of only two markers is needed to
completely separate nevi from melanoma, the experimental
costs are also relatively small. Our study could thus be used
to develop a practical protocol, which would complement
routine pathological examination and provide a clarification
when tissue sections show overlapping morphologic and
histologic features.
Despite significant progress in the identification of mo-
lecular pathways that drive tumorigenesis, melanoma still
poses a challenge to the scientific community. Owing to its
notorious resistance to chemotherapy, patients with malig-
nant melanoma have limited treatment options and have a
poor prognosis. Although, vemurafenib, a BrafV600E specific
inhibitor, showed impressive results in terms of response
rate and progression free survival, the responses are mostly
short-lived as seen by development of resistance in nearly
Figure 2 Classification and Regression tree for differentiating nevi from melanoma using Braf, nuclear p300 and cytoplasmic p300
expression. Nevi samples include both normal and dysplastic nevi cases. Melanoma samples include both primary and metastatic melanoma
cases. ‘n’ indicates the number of samples and ‘%’ indicates the percentage of samples available at the respective node. Improvement is an
indicator of separation achieved by the application of the respective marker to classify the parent node.
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iveness, like combining Braf inhibitors with MEK1/2 inhibi-
tors or small molecule inhibitors of the PI-3 kinase
pathway, are in various stages of clinical studies, but it is
too early to predict their clinical efficacy [6,25].
Our results from patient survival show that patients
with low Braf and high nuclear p300 expression have
better survival, hinting at the benefits of simultaneously
targeting Braf and nuclear p300 in treatment of melan-
oma. Data from our previous study showed that though
cytoplasmic p300 expression was significantly associated
with clinico-pathologic characteristics of melanoma, only
nuclear p300 had prognostic significance [10]. Even in
the present study, cytoplasmic p300 expression was only
informative during the diagnosis part of the analysis but
was not a significant prognostic factor (Table 4). Besides,
the major site of activity of p300 is in the nucleus where
it regulates critically important processes like transcrip-
tion and DNA repair [26-28]. Interestingly, loss ofanother well known histone acetyltransferase, TIP60,
was reported to be associated with worse prognosis in
melanoma patients [29]. We therefore think that
combining Braf inhibitors with HDAC inhibitors might
be beneficial in the chemotherapy of melanoma. Strik-
ingly, two HDAC inhibitors, vorinostat (Merck) and
romidepsin (Gloucester Pharmaceuticals), which report-
edly showed inhibitory effects on melanoma growth,
were approved by the US FDA for the treatment of cuta-
neous T-cell lymphoma [30-34]. A combination of tyro-
sine kinase & C-Raf inhibitor, Sorafenib and vorinostat is
currently being studied in the treatment of advanced
cancers [35], but we could not find any studies per-
formed using a combination of B-raf inhibitors and vori-
nostat or romidepsin. Our findings encourage further
research on the potential improved efficacy of coadmin-
istration of Braf and HDAC inhibitors.
Another finding of our study is the inverse correlation
between Braf and nuclear p300 and direct correlation
Figure 3 Classification and Regression tree for differentiating primary melanoma from metastatic melanoma using Braf, nuclear p300
and cytoplasmic p300 expression. PM, primary melanoma, includes AJCC stages I and II cases. MM, metastatic melanoma, includes stages III
and IV. ‘n’ indicates the number of samples and ‘%’ indicates the percentage of samples available at the respective node. Improvement is an
indicator of separation achieved by the application of the respective marker to classify the parent node.
Figure 4 Nuclear p300 expression and 5-year patient survival. Kaplan-Meier survival analyses of correlation between nuclear p300 expression
and 5-year overall (A) and disease-specific (B) survival of melanoma patients. The cases with low nuclear p300 expression are represented by
‘blue’ line and the cases with high expression are represented by ‘pink’ line.
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Figure 5 Braf and p300 expression and 5-year patient survival. Kaplan-Meier survival analyses of correlation between Braf & p300 expression
and 5-year overall (left panels) and disease-specific (right panels) survival of melanoma patients. (A and B) correlation between Braf and nuclear
p300 expression, and patient survival. (C and D) correlation between Braf and cytoplasmic p300 expression, and patient survival. Blue line
represents the cases with low Braf and low p300; pink line, cases with low Braf and high p300; yellow line, high Braf and low p300; sky blue line,
high Braf and high p300.
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suggests possible cross-talk between Braf and p300. Pre-
vious studies showed that phosphorylation of p300 could
differentially regulate its activity and protein stability
[36,37]. For example, while protein kinase C (PKC) and
salt inducible kinase 2 mediated phosphorylation at
serine-89 was reported to inhibit the HAT activity
[38,39], Akt mediated phosphorylation at serine-1834,
serine-2279, serine-2315, and serine-2366 was shown to
enhance the HAT activity of p300 [40-42]. Along those
lines, Akt and ERK2 mediated phosphorylation
was shown to stabilize p300 protein levels, but phos-
phorylation by mitogen activated protein kinaseTable 4 Multivariate Cox regression analysis on overall and d
Variables
Overall survival
ß† SE HR (95% CI) p-va
AJCC 1.302 0.170 3.68 (2.63-5.13) 1.98
Braf 0.178 0.190 1.20 (0.82-1.73) 0.34
Nuclear p300 −0.508 0.161 0.60 (0.44-0.83) 0.00
Cytoplasmic p300 0.049 0.163 1.05 (0.76-1.45) 0.76
Coding of variables: AJCC was coded as 1 (stages I & II) and 2 (stages (III & IV). Braf
†β: regression coefficient.
Abbreviations: SE standard error of β, HR hazard ratio, CI confidence interval.(MAPK) resulted in degradation of the p300 protein
[11,12,36,40,43]. However, none of the studies have so
far focused on the effect of phosphorylation on intracel-
lular distribution of p300. Our findings point to the
possible phosphorylation and altered localization of
p300 by Braf/MAPK signaling, which needs further
investigation.
While our database was relatively large with details of
several clinical characteristics, further studies are war-
ranted before drawing firm conclusions on the benefits
of combined Braf and HDAC inhibitors. Though the sig-
nificance of finding a correlation in patient biopsies can-
not be underestimated, evidence from studies at theisease-specific survival of primary melanoma patients
Disease-specific survival
lue ß SE HR (95% CI) p-value
× 10−14 1.457 0.182 4.29 (3.01-6.13) 1.13 × 10−14
8 0.110 0.196 1.12 (0.76-1.64) 0.575
2 −0.525 0.169 0.59 (0.42-0.82) 0.002
4 0.091 0.171 1.10 (0.78-1.53) 0.595
and p300 expression was coded as 1 (low staining) and 2 (high staining).
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tionship between Braf and p300. Furthermore, we did
not have enough cases with information on the status of
Braf mutations, so we were unable to analyze the poten-
tial correlation between BrafV600E and p300.
Conclusions
Our study elucidates the cross talk between Braf and
p300 in melanoma and suggests that Braf might nega-
tively regulate the accumulation of p300 in the nucleus
and promote the cytoplasmic localization of p300. We
also show that using a combination of Braf and p300 ex-
pression, it is possible to separate nevi and melanoma
samples, and primary and metastatic melanoma samples.
We show that patients with low Braf and high p300 ex-
pression have better prognosis, suggesting the possibility
of combining Braf and HDAC inhibitors in melanoma
treatment.
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